# EDGAR Filing Document

**Accession Number:** 0001982708
**File Stem:** 0001213900-25-109447
**Filing Date:** 2025-11
**Character Count:** 6165
**Document Hash:** 9cec94a59856e989361cf94f85ebc64a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-109447.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001213900-25-109447

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20251112

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Anbio Biotechnology
- **CENTRAL INDEX KEY:** 0001982708
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42526
- **FILM NUMBER:** 251474884

**BUSINESS ADDRESS:**
- **STREET 1:** FRIEDRICH-EBERT-ANLAGE 49
- **CITY:** FRANKFURT AM MAIN
- **STATE:** 2M
- **ZIP:** 60308
- **BUSINESS PHONE:** 4916096247281

**MAIL ADDRESS:**
- **STREET 1:** FRIEDRICH-EBERT-ANLAGE 49
- **CITY:** FRANKFURT AM MAIN
- **STATE:** 2M
- **ZIP:** 60308

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of November 2025**

**Commission File Number: 001-42526**

**Anbio Biotechnology**

**Wilhelm Gutbrod Str 21B, 60437,<br> Frankfurt am Main, <br> Germany<br> +49 16 0962 47281**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

**Changes in Company's Certifying Accountant**.

(1) Previous Independent Registered Public Accounting Firm

&nbsp;&nbsp;&nbsp;&nbsp;(i) Effective
 on November 10, 2025, Anbio Biotechnology (the "Company") terminated YCM CPA INC. as the
 Company's independent registered public accounting firm.

&nbsp;&nbsp;&nbsp;&nbsp;(ii) The reports
 of YCM CPA INC. on consolidated balance sheets of the Company for the fiscal year ended
December 31, 2024 and 2023 and the consolidated statements of comprehensive income (loss), consolidated statements of changes in equity,
and consolidated statements of cash flows for the fiscal years ended December 31, 2024, 2023 and 2022, did not contain an adverse opinion
or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

&nbsp;&nbsp;&nbsp;&nbsp;(iii) The decision
 to change the independent registered public accounting firm was approved by the Board of Directors of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(iv) During
 the Company's most recent fiscal year ended December 31, 2024 and through November 10, 2025, the date of dismissal, (a) there
 were no disagreements with YCM CPA INC. on any matter of accounting principles or practices, financial statement disclosure, or auditing
 scope or procedure, which disagreements, if not resolved to the satisfaction of YCM CPA INC., would have caused it to make reference
 thereto in its reports on the financial statements for such year and (b) there were no "reportable events" as described
 in Item 304(a)(1)(v) of Regulation S-K.

&nbsp;&nbsp;&nbsp;&nbsp;(v) The Company
 provided YCM CPA INC. with a copy of this Current Report and has requested that it furnish the Company with a letter addressed to
 the U.S. Securities and Exchange Commission stating whether it agrees with the above statements. A copy of such letter is attached
 as Exhibit 16.1 to this Report of Foreign Private Issuer on Form 6-K.

(2) New Independent Registered Public Accounting Firm

On November 10, 2025, the Board of Directors of the Company and the Audit Committee of the Company approved and ratified the appointment of HTL International, LLC as its new independent registered public accounting firm to audit the Company's financial statements, effective November 10, 2025. During the two most recent fiscal years ended December 31, 2024 and 2023 and any subsequent interim periods through the date hereof prior to the engagement of HTL International, LLC, neither the Company, nor someone on its behalf, has consulted HTL International, LLC regarding:

&nbsp;&nbsp;&nbsp;&nbsp;(i) either:
 the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that
 might be rendered on the Company's consolidated financial statements, and either a written report was provided to the Company
 or oral advice was provided that the new independent registered public accounting firm concluded was an important factor considered
 by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or

&nbsp;&nbsp;&nbsp;&nbsp;(ii) any matter
 that was either the subject of a disagreement as defined in paragraph 304(a)(1)(iv) of Regulation S-K or a reportable event as described
 in paragraph 304(a)(1)(v) of Regulation S-K.

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 16.1 | [Letter from YCM CPA INC. addressed to the U.S. Securities and Exchange Commission](ea026474701ex16-1_anbio.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Anbio Biotechnology** | **Anbio Biotechnology** |
| Date: November 12, 2025 | By: | */s/ Michael Lau* |
|  | Name: | Michael Lau |
|  | Title: | Chief Executive Officer |

---

## Exhibit 16.1

**Exhibit 16.1**

November 12, 2025

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Re: Anbio Biotechnology

CIK Number: 0001982708

Dear Commissioners:

We have read Form 6-K dated November 12, 2025 of Anbio Biotechnology ("Registrant") and are in agreement with the statements contained therein as it pertains to our firm; we are not in a position to agree or disagree with other statements of Registrant contained therein.

Very truly yours,

![](ex16-1_002.jpg)

/s/ YCM CPA INC.

Irvine, California